Results for tag: "Advanced Recurrent Ovarian Cancer Drug"

The Advanced Recurrent Ovarian Cancer Drug market is a subset of the larger Ovarian Cancer Drugs market. It focuses on drugs used to treat ovarian cancer that has recurred or become resistant to other treatments. These drugs are typically used in combination with other treatments, such as chemotherapy, to improve outcomes. They are often targeted therapies, meaning they are designed to target specific molecules or pathways in the cancer cells. Commonly used drugs in this market include PARP inhibitors, monoclonal antibodies, and immunotherapies. The Advanced Recurrent Ovarian Cancer Drug market is highly competitive, with many companies developing and marketing drugs for this indication. Some of the major players in this market include AstraZeneca, Merck, Pfizer, Roche, and Novartis. Show Less Read more